Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on Pacritinib PK in Healthy Subjects
NCT02807116Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pacritinib in myelofibrosis (MF), sponsored by CTI BioPharma Corp. Primary endpoint: Ratios of geometric mean values for pacritinib treatments with and without rifampin at Day 17. Started Jan 2015; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02807116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807116.